ArticleMicrobiology spectrum2023
Loss of a Branch Sugar in the Acinetobacter baumannii K3-Type Capsular Polysaccharide Due To Frameshifts in the
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Personalized Phage Therapy in an ICU Patient with Polymicrobial Pulmonary Infections: a case from a single-arm trial.Nature communications · 2026Article
- Article
- Multiple prophage acquisition events over the course of an outbreak drive lysogenic conversion of capsular polysaccharides produced by carbapenem-resistantMicrobiology spectrum · 2026Article
- Mobilization of the AbGRI4 resistance island inMicrobiology spectrum · 2026Article
- A conserved KL2-capsule-related phage-resistant mechanism in carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- Infection and resistance mechanisms of phage vB_VpM-PP270 iniScience · 2025Article
- Acinetobacter phages use distinct strategies to breach the capsule barrier.PLoS pathogens · 2025Article
- Characterization of phage HZY2308 against Acinetobacter baumannii and identification of phage-resistant bacteria.Virology journal · 2024Article
- Characterization of the carbapenem-resistantmSystems · 2024Article
- Lytic Capsule-SpecificViruses · 2024Article
- Host range expansion of Acinetobacter phage vB_Ab4_Hep4 driven by a spontaneous tail tubular mutation.Frontiers in cellular and infection microbiology · 2024Article
- Identification and characterization of the capsule depolymerase Dpo27 from phage IME-Ap7 specific toFrontiers in cellular and infection microbiology · 2024Article
- Review
- Genome-wide phage susceptibility analysis in Acinetobacter baumannii reveals capsule modulation strategies that determine phage infectivity.PLoS pathogens · 2023Article
- Article
- Review
- Structural diversity amongFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The type of capsular polysaccharide (CPS) on the cell surface of Acinetobacter baumannii can determine the specificity of lytic bacteriophage under consideration for therapeutic use. Here, we report the isolation of a phage on an extensively antibiotic resistant ST2 A. baumannii isolate AB5001 that carries the KL3 CPS biosynthesis gene cluster predicting a K3-type CPS. As the phage did not infect isolates carrying KL3 or KL22 and known to produce K3 CPS, the structure of the CPS isolated from A. baumannii AB5001 was determined. AB5001 produced a variant CPS form, K3-v1, that lacks the β-d-Glс
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.